Obinutuzumab

Obinutuzumab (called afutuzumab until 2009) is a humanized anti-CD20 monoclonal antibody, originated by GlycArt Biotechnology AG and developed by Roche as a cancer treatment.

Back Manual download

Message Consultation

If you have any questions about our products or services, please fill out the message below and we will give you feedback as soon as possible.

Name：
Phone：
Email：
Company Name：
Area：
Message：
Code：